CD38 and Miyoshi myopathy: In this single‐center, two‐arm, retrospective, real‐life study, we investigated the CMV reactivation rate in MM patients treated with the anti‐CD38 monoclonal antibody daratumumab as first‐ or second‐line therapy, and outcomes were compared to a daratumumab‐naïve control group.